Compared to CD133, CD44 is identified as a classic CSC marker and widely presents in various cancers including breast, stomach, glioma, colon, head and neck cancers [33–35], while CD133 mainly express in glioma, neural tumors and liver cancer. This evidence concerns the gene CD44 and central nervous system cancer.